Yahong Pharmaceutical announced that Jiangsu Beilian Biotechnology Co., Ltd., a holding subsidiary of the company, has received the “Drug Clinical Trial Approval Notice” issued by the State Drug Administration, and the company's self-developed APL-2501 has obtained clinical trial approval, and plans to conduct clinical trials on advanced solid tumors. APL-2501 is an anti-CLDN6/9 antibody drug conjugate. Its clinical trial application was previously approved by the US FDA. This approval will not have a significant impact on the company's recent performance, and there is uncertainty about drug development and subsequent marketing.

Yahong Pharmaceutical announced that Jiangsu Beilian Biotechnology Co., Ltd., a holding subsidiary of the company, has received the “Drug Clinical Trial Approval Notice” issued by the State Drug Administration, and the company's self-developed APL-2501 has obtained clinical trial approval, and plans to conduct clinical trials on advanced solid tumors. APL-2501 is an anti-CLDN6/9 antibody drug conjugate. Its clinical trial application was previously approved by the US FDA. This approval will not have a significant impact on the company's recent performance, and there is uncertainty about drug development and subsequent marketing.